SomaLogic, a proteomics technology company, went public via merger with CM Life Sciences II, a special purpose acquisition company sponsored by affiliates of Casdin Capital and Corvex Management, in a $1.2bn deal. The transaction included a fully committed PIPE of $375m from Casdin Capital, Corvex Management, Janus Henderson Investors, SoftBank, T.Rowe Price, ARK Invest, Farallon Capital, Perceptive Advisors, Morgan Stanley, Illumina, Soleus, Foresite and Novartis Pharma. "This is a powerful business combination for SomaLogic that will bring significant capital and intellectual resources to propel the next chapter of the company’s growth," Roy Smythe, SomaLogic CEO.